AiLNP

AiRNA

AiTEM

AI驱动`药物递送`和`药物发现`

AI-Driven `Drug Delivery` and `Drug Discovery`

<div class="media-wrap image-wrap align-center" style="text-align:center"><img class="media-wrap image-wrap align-center" src="https://oss.metispharmaceuticals.cn/c55703a5ed917fcd1ac20a2960c5af8b.jpg" width="656.667px" height="437px" style="width:656.667px;height:437px"/></div>At the beginning of the year of rabbit on January 9, 2023, METiS held the housewarming ceremony at Haiwei Center (Binjiang,Hangzhou) where its new office site located. More than 50 invited guests gathered at the venue, including government officers, investors and partners. Ms. She Jian, Deputy Head of Binjiang District, Mr. Wu Yibo, representative of investors, and Dr. Tang Qiusong, director of Roche Accelerator(China), delivered electric speeches.The newly-built site covers about 5,700 square meters, of which 3,000 square meters are laboratories, including a 1,500 square meter biological laboratory with class C and D clean rooms, which will enable the design, synthesis, purification of mRNA, LNP manufacturing process development, high-throughput cell efficacy evaluation, etc. The 1,500 square meter chemistry laboratory encompasses high-throughput formulation equipment, multi-dosage small molecule new drug development equipment, analysis laboratory, etc., which can be leveraged to achieve the R&amp;D of small molecule new drug formulation and process development, analytical method development and validation of small molecule &amp; mRNA drug, and it also paves the road for the end-to-end preclinical development capability of small molecule and mRNA drugs.<div class="media-wrap image-wrap align-center" style="text-align:center"><img class="media-wrap image-wrap align-center" src="https://oss.metispharmaceuticals.cn/fef8fbef599129eb8385e115b4520a88.png" width="961px" height="672px" style="width:961px;height:672px"/></div>She Jian, deputy head of Binjiang District, said, &quot;As a strategic emerging industry that Hangzhou government strives to forge, biomedicine has been recognized as imperative. Today, some young enterprises like METiS Pharmaceutical has brought new momentum to China and even the world&#x27;s biomedicine. We hope that in the future, METiS can get the utmost out of the advantages of technology platform and talent platform, and collaborate with pharmaceutical enterprises in Hangzhou to bolster the pharmaceutical industry in Hangzhou to be bigger and stronger. The district government will also continue to propell the development of enterprises and provide assistance within its capacity.&quot;Dr. Tang Qiusong, director of Roche Accelerator(China), said,&quot; The fruitful collaboration between China Roche Accelerator and METiS Pharmaceutical has proved that the cooperation and exchanges between emerging companies and large pharmaceutical companies can facilitate the advancement of research and development projects, which shed light on the significant value of business cooperation model. Roche sincerely hopes that METiS will expedite its development of the collaborated ‘delivery system project’ for a big leap into the rosy bio-ocean.&quot;Caida Lai, Ph.D., co-founder &amp;CEO of METiS, said, &quot; METiS has been pushing the envelope for years, and we have turned the tide of technology in 2022. Hundreds of LNP with proprietary right and breakthrough technology are generated from our cutting-edge AiLNP delivery Platform, which already created billion dollars of high-net-worth value. And we are looking forward to some more massive collaborations. We have successfully developed multi-organ targeted delivery, such as liver, lung, CNS and tumor tissues, and achieved long-term release in local site. These technological breakthroughs open huge opportunities for unmet clinical needs of human beings such as cancer and neurological diseases.&quot;In 2022, we upgraded from a technology platform to a product platform. We are developing new modality formulations and a number of breakthrough small molecule reformulations benefiting from AiTEM platform’s technology. MTS004 is expected to start phase III in the first half of this year. MTS004 can treat Pseudobulbar affect, which affects millions of cerebral stroke patients, Parkinson patients and other patients in China. METiS will bring the first therapeutic drug for this indication in China to meet the huge clinical demand. In addition, we have generated billion dollars value in pipeline by developing blockbuster drugs in some complex formulations, the worth-mentioning long-acting oral sustained-release that address critical pain points, such gastrointestinal adverse reactions, toxicity reduction, and efficacy synergism in multiple tumors and rare diseases.&quot;The &quot;AI+ Drug Delivery and Discovery&quot; seminar was held in the afternoon. Several R&amp;D execs shared wonderful technologies from the perspective of high-throughput formulation development, long-acting formulation development, LNP design, mRNA design, quantum computing, artificial intelligence AI algorithm and so on. At the same time, homing in on &quot;RNA and gene therapy industry opportunities and challenges, application scenarios, strategy deployment and corner overtaking opportunities&quot;, Dr. Caida Lai held a round-table discussion with Guo Xiaodi, Chief scientist and Director of Pharmaceutical Research Institute of Huahai Pharmaceutical, Haijun Yu, Researcher of Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Yun Yang, co-founder and CFO of Circode Biology, and Wang Kai, Researcher of School of Basic Medical science, Peking University. Universal recognition has been given to the huge development prospect of RNA and gene drugs in the future, as well as the potential of AI enabling RNA, gene drugs R&amp;D and its optimization.<div class="media-wrap image-wrap align-center" style="text-align:center"><img src="https://oss.metispharmaceuticals.cn/02db89967e9dd0c20d9d48f7fa511f07.png" width="671.6666870117188" height="454" style="width:671.6666870117188px;height:454px"/></div>Since its inception, METiS has always been clinical demand-oriented, exploring the path of artificial intelligence-driven drug delivery and drug discovery innovation, and achieving many technological breakthroughs and application expansion. The commissioning of the new site is an great leap in the company&#x27;s continued exploration and expansion in the field of drug development and delivery. Ring in the new and look to the future. In 2023, METiS will continue to achieve new technological breakthroughs, optimize the technology platform, and strive to advance to the blue ocean of &quot;AI+ drug delivery and discovery&quot; with the support and company from many others.

辞旧迎新，展望未来。剂泰医药在2023年还将继续实现新的技术突破，优化技术平台，在多方的支持与陪伴下向「AI+药物递送与发现」蓝海不断进发！

Ring in the new and look to the future. In 2023, METiS will continue to achieve new technological breakthroughs, optimize the technology platform, and strive to advance to the blue ocean of "

剂泰医药乔迁仪式暨「AI+药物递送与发现」专题研讨会圆满举行

METiS Held the ‘AI+ Drug Delivery & Drug Discovery’ Seminar & the Housewarming Ceremony

Recently, Small and Medium Enterprise Administration, directed by Ministry of Industry and Information Technology has released the top 500 list in the 7th ‘MAKER IN CHINA’ contest. The contest has covered 35 regional competitions, 6 industrial chain collaboration competitions, 5 specific competitions in key industries, and 1 oversea competition. More than 37,000 SMEs were signed up, and it is an increase of 18% on a YOY basis.Not long ago in June of the same year, METiS participated in the &quot;Maker Beijing 2022&quot; contest which was jointly sponsored by the Municipal Bureau of Economy and Information Technology, the Municipal Bureau of Finance, and the People&#x27;s Government of Fengtai District of Beijing. Dr. Caida Lai, CEO, and Dr. Andong Liu, VP of Innovative Technology participated in the competition. METiS’s project named as &quot;Driving Drug Delivery Development&quot; was awarded as a TOP150 project. As the winning project of Beijing Regional Competition, METiS was successfully recommended by the competent authorities to participate in the &quot;Maker China&quot; SME Innovation and Entrepreneurship Contest. Finally, it set apart from 150 high-quality projects and was honored as the top 500 with a pass through the public notification period.<div class="media-wrap image-wrap align-center" style="text-align:center"><img class="media-wrap image-wrap align-center" src="https://oss.metispharmaceuticals.cn/61b6b3c7291bec902fccef47c46cd8cc.jpg" width="620px" height="797px" style="width:620px;height:797px"/></div>From ‘MAKER IN CHINA’ Official WebsiteMAKER in BEIJING 2022‘MAKER in BEIJING 2022’ Innovation and Entrepreneurship Contest was jointly sponsored by the Municipal Bureau of Economy and Information Technology, the Municipal Bureau of Finance, and the People&#x27;s Government of Fengtai District of Beijing. The contest covers Regional Chapters and Leading Cooperates Competitions, and it is based on the theme of ‘Maker in Beijing, Intelligence for Future’.  The contest aiming at taking the regional advantage of Beijing as a center of science and technology Innovation to push the envelope to against the risks of pandemic, economy &amp;employment slump and stagnant development, and to create a broad platform for small and medium-sized enterprises and makers to exchanging ideas, collaboration, projects incubation. It is endeavored to beef up the industrial ecology of collaborative innovation, resource sharing and integrated development between large enterprises and small and medium-sized enterprises.About ‘MAKER IN CHINA’ SMES ContestThe &quot;Maker in China&quot; SME Innovation and Entrepreneurship Contest was jointly organized by the Ministry of Industry and Information Technology and the Ministry of Finance, is aiming at motivating innovation, aggregating entrepreneurship resources, building innovative entrepreneurial climate, and developing a platform for small and medium-sized enterprises (SMEs) to exchanging ideas, collaboration, projects incubation. The contest is also aiming at discovering and fostering a number of outstanding projects, creating new products, new technology, new pattern and new industrial form, facilitating the transformation and upgrading of small and medium-sized enterprises to be more professional, refined, specialized and innovative, driving integrated innovation among large, small and medium-sized enterprises, and bolstering manufacturing power and cyber power of China.About METiSMETiS Pharmaceuticals is a biotechnology company that aims to address unmet clinical needs by integrating drug delivery and drug discovery with artificial intelligence, machine learning and quantum simulation to find optimal therapies across a broad spectrum of disease areas. Business Collaboration<a href="mailto:sarenty@metispharmaceuticals.com">sarenty@metispharmaceuticals.com</a> Media<a href="mailto:pr@metispharmaceuticals.com">pr@metispharmaceuticals.com</a>

剂泰医药参赛项目作为北京区域赛获奖项目，顺利获得主管部门推荐，参与到此次“创客中国”中小企业创新创业大赛当中，最终从150个优质项目中脱颖而出，荣幸获选大赛500强，并通过了公示期。

METiS was successfully recommended by the competent authorities to participate in the "Maker China" SME Innovation and Entrepreneurship Contest. Finally, it set apart from 150 high-quality pr

剂泰医药获选“创客中国”中小企业创新创业大赛500强

METiS Got Tapped as Top 500 SME Innovation and Entrepreneurship Contest by ‘MAKER IN CHINA’

The Hurun Research Institute recently released the Hurun Global Gazelle Index 2022 Half-Year Report. Out of many biotech companies, METiS found a remarkable spot in the list.<div class="media-wrap image-wrap align-center" style="text-align:center"><img src="https://oss.metispharmaceuticals.cn/c5c3f436ab1ecbf849bc43d5ae3190c1.jpg" width="670" height="297" style="width:670px;height:297px"/></div>The report listed companies founded after 2000, with high growth potential of US$1bn valuation mark within 3 years, which are most likely to ‘go unicorn’. The valuation of the listed Gazelles ranging from US$ 500mn to US$ 1 Bn. Hurun Research has been tracking Unicorns since 2017 and Gazelles since 2018. This is the second edition of the Hurun Global Gazelle Index.Hurun Research found 621 Gazelles in the world, based in 33 countries and 151 cities. On average, they were set up in 2015, 74% of them selling software and services and only 26% selling physical products. 58% are selling to businesses, whilst 42% are consumer-facing. Gazelles were disrupting healthcare, financial services and business management solutions.full list at：https://mp.weixin.qq.com/s/8qSt5QEJIFSMCzDKOr2qzg

《2022年中胡润全球瞪羚企业》列出了成立于2000年之后、三年内最有可能达到独角兽级十亿美金估值的高成长性企业。

The report listed companies founded after 2000, with high growth potential of US$1bn valuation mark within 3 years, which are most likely to ‘go unicorn’. 

剂泰医药荣登胡润研究院《2022年中胡润全球瞪羚企业》

METiS Got Recognized in Hurun Global Gazelle Index 2022 Half-Year Report

<a href="https://oss.metispharmaceuticals.cn/8b7548924bddec55e7690ef05e403bc3.zip" target="_blank">0.zip</a>The 16th CCKS was held in Qinhuangdao on August 26, 2022. CCKS technology evaluation aims to provide a platform and resources for researchers to test knowledge graph and semantic computing technologies, algorithms and systems, bolster the technological development in the field of knowledge graph in China, and promote the integration and coordination of academic achievements and industrial needs. The official announcement disclosed that there are 14 evaluation tasks in this year, encompassing 5 topics in fields of finance, education, military, chemical and etc.; 5,362 teams with nearly 23,000 people participated in the competition. Yang Wenming, Yin Le and Zou Jiali, members of the AI department of METiS Pharmaceuticals, stood out from many other teams and won the evaluation task competition of &quot; Construction and Application of Chemical Elemental Knowledge Graph &quot; with absolute superiority. <div class="media-wrap image-wrap align-center" style="text-align:center"><img class="media-wrap image-wrap align-center" src="https://oss.metispharmaceuticals.cn/3f90a203beea45df01711b79608907a9.jpg" width="682.484px" height="478px" style="width:682.484px;height:478px"/></div><div class="media-wrap image-wrap align-center" style="text-align:center"><img class="media-wrap image-wrap align-center" src="https://oss.metispharmaceuticals.cn/69a2e8b1bd3a2358a3c89630894e55cd.jpg" width="662px" height="440.988px" style="width:662px;height:440.988px"/></div>The main intention of compound property prediction is to find compounds with substandard physical and chemical properties in a short time, so as to reduce risk when candidates entering into clinical trials and improve the drug development success rate. The traditional method of compound property prediction and analysis is usually from experiments, which is costly and time-consuming. A lot of research work has proved that the machine learning technology, especially the depth study on compound property prediction, has huge utilization potential. The drug research and development work are implemented by using sequence (SMILES) or graphs (atomic for the node, chemical bonds for edge) to indicate compounds, and leveraging sequence modeling or graph neural network (GNN) to predict the properties of the compound, so as to improve the efficiency and reduce the research cycle. However, these approaches usually only take the structural information of compound molecules into consideration not the chemical knowledge. Therefore, the organizer constructed the chemical element knowledge graph based on the periodic table of chemical elements, and brought forward the evaluation tasks in regard to the key technologies and applications of the knowledge graph construction.METiS team exploited the following approaches to study the compound molecules: 1) Graph data pre-training technology, the atoms in the molecule are regarded as nodes, chemical bonds as edges, and the chemical molecule as a graph data; 2) Molecular descriptors; 3) Pharmacophore fingerprints. In the pre-training model, 2D information, 3D information and functional groups, etc. of chemical molecules are included comprehensively. Based on the above different approaches, feature vectors are generated to characterize molecules. Secondly, descending the high dimensional sparse vectors (functional group) into lower dimensional dense ones, then integrate these vectors that with various features to generate the ultimate vector characteristic. Lastly, import those vector characteristics for prediction from integrated model, which foretell a precise compound characteristic. Refer to the ensuing disclosed evaluation paper in CCKS2022 for specific methods.“Compound property prediction based on multiple different molecular features and ensemble learning”（website：www.sigkg.cn/ccks2022）<div class="media-wrap image-wrap align-center" style="text-align:center"><img class="media-wrap image-wrap align-center" src="https://oss.metispharmaceuticals.cn/bd02f5344ccec74a51b2b505358b6b8d.png" width="877.491px" height="268px" style="width:877.491px;height:268px"/></div>Schematic Diagram for Molecular CharacterizationThe integration of Pharmacoprint (Gobbi) can improve the final evaluation metrics, but pharmacophore fingerprint is a high-dimensional sparse vector, mainly composed of 0 or 1. For such features with excessive dimensions, AutoEncoder is used to reduce dimension, and label information is also fully used in the process of dimension reduction. The model structure is shown in the following figure. The processed molecular characteristics are spliced and merged, and then import into the model for training.<div class="media-wrap image-wrap align-center" style="text-align:center"><img class="media-wrap image-wrap align-center" src="https://oss.metispharmaceuticals.cn/d51023379ed300462f4b62ebe9ce7e82.png" width="597.993px" height="362px" style="width:597.993px;height:362px"/></div>The winning demonstrated that METiS has made great progress in the field of AI pharmaceutical in terms of the capability of algorithm and model building .<div class="media-wrap image-wrap align-center" style="text-align:center"><img class="media-wrap image-wrap align-center" src="https://oss.metispharmaceuticals.cn/5561f75be6f8f25b1273098cdebd8f2c.png" width="823px" height="204.479px" style="width:823px;height:204.479px"/></div>Now, the team&#x27;s technical solution has been successfully applied to the AiLNP &amp; AiTEM , two core technology platform of METiS. It is an efficient supportive tool for prediction of LNP and solid dispersion system, enabling &quot;AI + pharmaceutical&quot;, shortening the development cycle, improving the R&amp;D efficiency, to achieve more effective innovational delivery material design and more advantageous formulation system. In the future, METiS will endeavor to make great efforts in fundamental research and pharmaceutical R&amp;D in AI pharmaceutical by virtue of its leading scientific research and innovation ability, continue exploring the uncharted area of biology and pharmaceutical benefit from AI technology, to ultimately address the unmet clinical needs. About usMETiS is a biotechnology company that aims to drive optimal therapies across a broad spectrum of diseases by combining drug delivery and drug discovery with artificial intelligence, machine learning, and quantum simulation to address unmet clinical needs. The core team is led by NAE member and a number of MIT scientists, including drug development experts from well-known pharmaceutical companies such as Regeneron, Amgen and Novartis, as well as young talents in artificial intelligence and computing. The participants, Wenming Yang and Jiali Zou, also won the third place in the evaluation task of Medical Named Entity Recognition of CCKS2020.Based on the underlying technology, METiS has built the proprietary core technology platform of AiLNP, AiRNA and AiTEM to predict the physical and chemical and biological characteristics of small molecules and nucleic acid-based drugs in a specific microenvironment. METiS harnessed AI to drive the dry and wet experiment iteration to achieve more effective innovative design, especially in delivery material, nucleic acid sequence and optimization, for a more superior formulation and nucleic acid-based delivery system.AiLNP:AiLNP is an independent developed and self-owned platform, LNP library with a magnitude of tens of thousands of cationic lipids, and it is with independent IP rights of LNP delivery systems. The expression efficiency surpasses the industry standard for more than ten times. At the same time, LNP-based delivery targeting liver, lung, spleen, muscle and organs, tissues, etc., will enable the therapeutics such as, local regeneration, systematic, targeted protein secretion, antibody, enzyme replacement, tumor targeting, and enhance the immune therapy. The delivery and technology success has brought about a number of pipeline cooperation opportunities either from domestic or foreign large pharmaceutical companies.AiRNA: AiRNA uses quantum chemistry and machine learning algorithms, and combines the biological and physicochemical properties of nucleic acids to enhance large-scale design of the full-length mRNA sequence space. It is an mRNA synthesis and purification platform where mRNAs can be rapidly produced, tested in vivo and in vitro, optimized through AI models and experimental iterations, and eventually the mRNA sequences with high stability and high expression efficiency can be effectively designed.AiTEM: AiTEM establishes large-scale design space of formulations. It can generate tens of thousands of formulations per week and obtain the optimal ones within one month. By developing formulations such as solid dispersions, pharmaceutical gels, self-emulsifying granules, and nanoemulsions, or by solubilizing the insoluble compounds, the problems of insoluble and impermeable drugs can be solved.

团队的技术方案已成功运用到剂泰医药的核心技术平台AiLNP和AiTEM中，高效支撑脂质体LNP预测和固分体体系预测两大技术模块。

Now, the team's technical solution has been successfully applied to the AiLNP & AiTEM , two core technology platform of METiS. It is an efficient supportive tool for prediction of LNP and sol

剂泰医药斩获 CCKS 2022 化学知识图谱构建和应用评测冠军

A Recognition from CCKS2022, METiS Snagged First Prize for its Construction and Application of Chemical Elemental Knowledge Graph

剂泰医药（METiS）是全球首家以人工智能驱动药物递送和药物发现的生物技术公司，集合人工智能、机器学习和量子模拟等先进技术，旨在实现更有效的创新递送材料设计、候选药物选择和制剂设计、“可编程核酸药物”开发与核酸递送设计。

核心技术

业务|Business

管线|Pipeline

剂泰医药乔迁仪式暨「AI+药物递送与发现」专题研讨会圆满举行

剂泰医药获选“创客中国”中小企业创新创业大赛500强

剂泰医药荣登胡润研究院《2022年中胡润全球瞪羚企业》

剂泰医药斩获 CCKS 2022 化学知识图谱构建和应用评测冠军